Ganirelix
Aliases: Orgalutran · Fyremadel
Last verified: 2026-09-23
The short version
A GnRH antagonist for IVF — prevents premature ovulation during stimulation.
Identity & type
- Molecular type
- peptide
- Origin
- A GnRH antagonist for IVF — prevents premature ovulation during stimulation.
Mechanism of action
Competitive GnRHR blockade.
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. 0.25 mg SC daily.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
0.25 mg SC daily. Same as cetrorelix — an IVF antagonist with reliable ovulation blockade; mild injection-site reactions.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Same as cetrorelix — an IVF antagonist with reliable ovulation blockade; mild injection-site reactions.
Protocol — official vs community
Official / label
Orgalutran/Fyremadel (IVF): 0.25 mg SC once daily starting on stimulation day 5–6, continued daily until the day of hCG administration.
Duration: Days-long, covering the stimulation phase (typically 4–10 days).
Pharmacologically interchangeable with cetrorelix in practice; the choice between them is regional and commercial. Clinic-administered only.
Community (anecdotal)
Structured protocol data for this entry is coming.
Human evidence
Standard IVF.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Local reactions, headache.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials